Exhibit 99.1
EVHC News - For Immediate Release
|
Contact: |
Bob East |
|
|
Westwicke Partners |
|
|
443-213-0502 |
|
|
Bob.East@westwicke.com |
ENVISION HEALTHCARE REPORTS THIRD QUARTER ADJUSTED EPS OF $0.35, AN INCREASE IN NET REVENUE OF 20.3% AND AN INCREASE IN ADJUSTED EBITDA OF 25.1%
Greenwood Village, Colo. (November 5, 2014) — Envision Healthcare Holdings, Inc. (NYSE: EVHC) (EVHC or Company) announces results for the third quarter ended September 30, 2014. All comparisons included in this release are for third quarter 2014 to third quarter 2013 unless otherwise noted.
Third Quarter 2014 Highlights:
· Adjusted EPS was $0.35 and GAAP diluted EPS was $0.28;
· Net revenue was $1.15 billion, an increase of 20.3%;
· Adjusted EBITDA was $152.2 million, an increase of 25.1%; and
· Completed agreements with Ascension Health and two additional hospital systems for post-acute services.
William A. Sanger, president and chief executive officer, said, “The third quarter was another successful period for the company. On a consolidated basis, we achieved 20.3% top-line growth, driven by organic growth of 14.6% and acquisition growth of 5.7%, resulting in EBITDA growth of 25.1%. EmCare’s revenue growth of 23.6% was led by net new contract wins. AMR continued to deliver exceptional performance with revenue growth of 14.7%.
“The demand for our integrated service offerings remains strong across all business segments and our pipeline continues to expand. We continue to lead the market in the development of innovative solutions that enhance our core service offerings and improve care delivery for hospitals, health plans and communities.
“With respect to Evolution Health, in addition to our previously announced national agreements with Fundamental and Ascension Health, we recently entered into agreements with Universal Health Services and Memorial Hermann Health System. These agreements and our robust pipeline are evidence of the success and market receptivity of the Evolution Health model. ”
1
Results of Operations for the Third Quarter 2014
For the third quarter of 2014, EVHC generated net revenue of $1.15 billion, an increase of 20.3%.
Adjusted EBITDA was $152.2 million, an increase of 25.1%. This was primarily attributable to the impact of net new contract wins, improved volumes, a favorable shift in payor mix, effective expense control and acquisitions completed over the last 12 months. Income from operations was $113.9 million, an increase of 79.4%.
EVHC generated net income of $52.8 million, compared to net loss of $7.7 million. The increase in net income was primarily attributable to an increase in income from operations and the net impact of debt retirements in 2014 and 2013.
Segment Results for the Third Quarter 2014
EVHC operates two business segments: EmCare Holdings, Inc. (EmCare), the Company’s facility-based and post-acute care physician services segment and American Medical Response, Inc. (AMR), the Company’s healthcare transportation services segment.
EmCare
EmCare generated net revenue of $748.1 million, an increase of 23.6%, or $143.0 million. Organic growth was 17.7%, driven by an increase of 11.0% from net new contracts and an increase of 6.7% from same store contracts. Acquisition growth was 5.9%. On a same store basis, net revenue grew 7.9%, including volume increases of 6.3%, primarily due to additional volumes in both Medicaid expansion and non-expansion states, and net rate increases of 1.6%.
Adjusted EBITDA was $99.7 million, an increase of 21.6%, or $17.7 million. The increase in Adjusted EBITDA was primarily driven by revenue increases from net new contracts, same store revenue growth, acquisitions, favorable operating expense and insurance trends, offset by approximately $2.2 million for both infrastructure investments for Evolution Health and acquisition costs.
American Medical Response
AMR generated net revenue of $402.2 million, an increase of 14.7%, or $51.4 million. Organic growth increased 9.6%, driven by 4.0% from net new contract wins and 5.6% in existing markets. The 5.6% in existing markets included a 4.9% volume increase, primarily due to additional volumes in both Medicaid expansion and non-expansion states, and a 0.7% revenue increase per weighted transport. Acquisitions contributed 5.1% to revenue growth.
Adjusted EBITDA was $52.5 million, an increase of 32.5%, or $12.9 million. The increase was attributable to revenue increases, the actualization of cost improvements, primarily driven by deployment and staffing efficiencies, and favorable insurance trends.
Cash Flows for the Third Quarter 2014
Cash provided by operating activities was $100.1 million, compared to $31.7 million. This improvement was driven by an increase in net income and cash collections and a decrease in cash interest payments in 2014 and non-recurring cash outflows that occurred in 2013. EmCare Days Sales Outstanding (DSO) decreased by two days in the quarter.
Net cash used in investing activities was $40.0 million, compared to $42.3 million.
2
Net cash provided by financing activities was $24.5 million, compared to $549.3 million. This was primarily due to the 2013 net impact of our initial public offering and the redemption of the 2017 PIK notes. At September 30, 2014, there were no amounts outstanding under the ABL Facility.
Adjusted Free Cash Flow was $82.8 million, compared to $35.4 million.
Results of Operations for the Nine Months ended September 30, 2014
EVHC net revenue was $3.24 billion, an increase of 18.1%.
Adjusted EBITDA was $396.4 million, an increase of 20.7%. This increase was primarily attributable to the impact of increased revenue from net new contracts and existing contracts, effective expense controls, healthcare reform and acquisitions completed over the past 12 months. Income from operations was $275.4 million, an increase of 43.4%.
EVHC generated net income of $75.6 million, compared to net loss of $1.9 million. The increase in net income was primarily attributable to an increase in income from operations and the net impact of debt retirements in 2014 and 2013.
Segment Results for the Nine Months ended September 30, 2014
EmCare’s net revenue was $2.08 billion, an increase of 20.4%. Adjusted EBITDA was $258.2 million, an increase of 18.0%.
AMR’s net revenue was $1.16 billion, an increase of 14.1%. Adjusted EBITDA was $138.2 million, an increase of 25.8%.
Cash Flows for the Nine Months Ended September 30, 2014
Cash provided by operating activities was $194.0 million, compared to $25.6 million. The change was primarily driven by improvements in net income; cash collections, driven by a 5 day decrease in EmCare DSO; lower interest payments in 2014 and non-recurring outflows in 2013.
Net cash used in investing activities was $264.6 million, compared to $70.0 million. The increase in cash used for investing was primarily driven by acquisitions which were $199.3 million, compared to $27.4 million.
Net cash provided by financing activities was $113.1 million, compared to $562.3 million. This was primarily due to the 2013 net impact of our initial public offering and bond refinancing.
Adjusted Free Cash Flow was $167.2 million compared to $44.3 million.
2014 Guidance
The Company reaffirms 2014 Adjusted EPS guidance of $1.15 to $1.20 and Adjusted EBITDA guidance of $553 million to $558 million.
Conference Call
EVHC management will host a conference call today, Wednesday, November 5, 2014, at 5 p.m. Eastern Time, to discuss the Company’s financial results. Interested participants may listen to the call by dialing 800-857-6466, or
3
517-623-4761 for international callers, and referencing participant code 60012 approximately 15 minutes prior to the call. For those unable to participate in the live call, a replay will be available one hour after the call ends through December 5, 2014. To access the replay, dial 800-627-5350, or 402-220-0228 for international callers, and enter access code 6802. An audio file will be archived for 30 days on the investor relations section of the Company’s website: investor.evhc.net.
About Envision Healthcare Holdings, Inc.
Envision Healthcare Holdings, Inc., and our more than 32,000 employees and affiliated clinicians, offers an array of healthcare related services to consumers, hospitals, healthcare systems, health plans and local, state and national government entities. Through Envision Healthcare Corporation, we operate American Medical Response, Inc. (AMR), EmCare Holdings, Inc. (EmCare) and Evolution Health, LLC (Evolution Health). AMR is a provider and manager of community-based medical transportation services, including emergency (‘911’), non-emergency, managed transportation, fixed-wing air ambulance and disaster response. EmCare is a provider of integrated facility-based physician services, including emergency, anesthesiology, hospitalist/inpatient care, radiology, tele-radiology and surgery. Evolution Health provides comprehensive care to patients across various settings, many of whom suffer from advanced illnesses and chronic diseases. We are headquartered in Greenwood Village, Colorado. For additional information, visit www.evhc.net.
Forward-Looking Statements
Certain statements and information herein may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our 2014 Adjusted EBITDA and Adjusted EPS guidance, objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Any forward-looking statements herein are made as of the date of this press release, and EVHC undertakes no duty to update or revise any such statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in EVHC’s filings with the U.S. Securities and Exchange Commission from time to time, including in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q and subsequent periodic reports. Among the factors that could cause future results to differ materially from those provided in this press release are: decreases in our revenue and profit margin under our fee-for-service contracts due to changes in volume, payor mix and third party reimbursement rates, including from political discord in the federal budgeting process; the loss of existing contracts; failure to accurately assess costs under new contracts; difficulties in our ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; failure to implement some or all of our business strategies, including our efforts to grow our Evolution Health business and cross-sell our services; lawsuits for which we are not fully reserved; the adequacy of our insurance coverage and insurance reserves; our ability to successfully integrate strategic acquisitions; the high level of competition in the markets we serve; the cost of capital expenditures to maintain and upgrade our vehicle fleet and medical equipment; the loss of one or more members of our senior management team; our ability to maintain or implement complex information systems; disruptions in disaster recovery systems or management continuity planning; our ability to adequately protect our intellectual property and other proprietary rights or to defend against intellectual property infringement claims; challenges by tax authorities on our treatment of certain physicians as independent contractors; the impact of labor union representation; the impact of fluctuations in results due to our national contract with FEMA; potential penalties or changes to our operations, including our ability to collect accounts receivable if we fail to comply with extensive and complex government regulation of our industry; the impact of changes in the healthcare industry, including changes due to healthcare reform; our ability to timely enroll our providers in the Medicare program; our ability to restructure our operations to comply with future changes in government regulation; the
4
outcome of government investigations of certain of our business practices; our ability to comply with the terms of our settlement agreements with the government; our ability to generate cash flow to service our substantial debt obligations; the significant influence of investment funds sponsored by, or affiliated with, Clayton, Dubilier & Rice, LLC over us; and the factors discussed in “Risk Factors” in the Company’s Quarterly Report on Form 10-Q and subsequent periodic reports.
Non-GAAP Financial Measures Description and Reconciliation
This press release includes presentations of Adjusted EBITDA, Adjusted Free Cash Flow and Adjusted EPS, which are not financial measures calculated and presented in accordance with generally accepted accounting principles in the United States of America (GAAP). Adjusted EBITDA is defined as net income (loss) before equity in earnings of unconsolidated subsidiary, income tax benefit (expense), loss on early debt extinguishment, other income (expense), net, realized gains (losses) on investments, interest expense, net, equity-based compensation expense, related party management fees, restructuring charges, and depreciation and amortization expense. Adjusted Free Cash Flow is defined as cash flow from operations adjusted for cash used in non-acquisition related investing activities and certain out-of-period or non-recurring cash payments. Adjusted EPS is defined as diluted earnings per share adjusted for expenses related to the Company’s secondary offering, amortization expense, equity-based compensation expense, restructuring charges and loss on early debt extinguishment, net of an estimated tax benefit.
These non-GAAP financial measures are commonly used by management and investors as performance measures or liquidity indicators. However, the items excluded from these non-GAAP financial measures are significant components in understanding and assessing the Company’s financial performance, and as a result, these measures should not be considered in isolation or as an alternative to GAAP measures such as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in the Company’s consolidated financial statements as an indicator of financial performance or liquidity. Since these non-GAAP financial measures are not measures determined in accordance with GAAP and are susceptible to varying calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies. Reconciliations of non-GAAP financial measures are provided in this press release. Reconciliation for the forward-looking full-year 2014 Adjusted EBITDA and Adjusted EPS projections presented herein is not being provided due to the number of variables in the projected full-year 2014 Adjusted EBITDA and Adjusted EPS ranges and thus the Company does not currently have sufficient data to accurately estimate the individual adjustments for such a reconciliation.
5
Envision Healthcare Holdings, Inc.
Consolidated Statements of Operations and Other Information
(unaudited; in thousands, except shares, per share data and other information)
|
|
|
Quarter ended September 30, |
|
Nine months ended September 30, |
|
|
|
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenue |
|
$ |
1,150,329 |
|
$ |
955,888 |
|
$ |
3,239,867 |
|
$ |
2,743,467 |
|
|
Compensation and benefits |
|
819,353 |
|
677,797 |
|
2,330,021 |
|
1,963,546 |
|
|
Operating expenses |
|
129,535 |
|
110,387 |
|
364,885 |
|
313,145 |
|
|
Insurance expense |
|
27,527 |
|
26,974 |
|
90,091 |
|
78,647 |
|
|
Selling, general and administrative expenses |
|
22,851 |
|
40,733 |
|
65,820 |
|
86,521 |
|
|
Depreciation and amortization expense |
|
36,796 |
|
35,175 |
|
108,786 |
|
104,552 |
|
|
Restructuring charges |
|
366 |
|
1,319 |
|
4,906 |
|
4,988 |
|
|
Income from operations |
|
113,901 |
|
63,503 |
|
275,358 |
|
192,068 |
|
|
Interest income from restricted assets |
|
175 |
|
2 |
|
507 |
|
634 |
|
|
Interest expense, net |
|
(25,742 |
) |
(46,772 |
) |
(84,793 |
) |
(148,526 |
) |
|
Realized gains (losses) on investments |
|
(466 |
) |
158 |
|
648 |
|
276 |
|
|
Other income (expense), net |
|
(660 |
) |
(52 |
) |
(3,432 |
) |
(13,022 |
) |
|
Loss on early debt extinguishment |
|
— |
|
(29,519 |
) |
(66,397 |
) |
(29,641 |
) |
|
Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary |
|
87,208 |
|
(12,680 |
) |
121,891 |
|
1,789 |
|
|
Income tax benefit (expense) |
|
(34,437 |
) |
4,949 |
|
(49,700 |
) |
(3,932 |
) |
|
Equity in earnings of unconsolidated subsidiary |
|
72 |
|
68 |
|
185 |
|
230 |
|
|
Net income (loss) |
|
52,843 |
|
(7,663 |
) |
72,376 |
|
(1,913 |
) |
|
Add: Net (income) loss attributable to noncontrolling interest |
|
(67 |
) |
— |
|
3,233 |
|
— |
|
|
Net income (loss) attributable to Envision Healthcare Holdings, Inc. |
|
52,776 |
|
(7,663 |
) |
75,609 |
|
(1,913 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per common share |
|
$ |
0.29 |
|
$ |
(0.05 |
) |
$ |
0.42 |
|
$ |
(0.01 |
) |
|
Diluted earnings per common share |
|
$ |
0.28 |
|
$ |
(0.05 |
) |
$ |
0.40 |
|
$ |
(0.01 |
) |
|
Weighted average common shares outstanding, basic |
|
182,564,837 |
|
157,282,885 |
|
181,502,232 |
|
139,969,940 |
|
|
Weighted average common shares outstanding, diluted |
|
190,184,323 |
|
157,282,885 |
|
189,707,609 |
|
139,969,940 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Information |
|
|
|
|
|
|
|
|
|
|
EmCare weighted patient encounters |
|
3,835,925 |
|
3,081,561 |
|
10,720,502 |
|
8,955,616 |
|
|
AMR weighted transports |
|
795,424 |
|
700,288 |
|
2,319,595 |
|
2,094,887 |
|
Earnings Per Share Reconciliation
|
|
|
Quarter ended
September 30, 2014 |
|
Quarter ended
September 30, 2013 |
|
Nine months ended
September 30, 2014 |
|
Nine months ended
September 30, 2013 |
|
|
Weighted average common shares outstanding, diluted |
|
190,184,323 |
|
157,282,885 |
|
189,707,609 |
|
139,969,940 |
|
|
Adjustment to dilute basic shares |
|
— |
|
8,671,280 |
|
— |
|
6,023,306 |
|
|
Adjusted diluted shares |
|
190,184,323 |
|
165,954,165 |
|
189,707,609 |
|
145,993,246 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income attributable to Envision Healthcare Holdings, Inc. |
|
$ |
52,776 |
|
$ |
(7,663 |
) |
$ |
75,609 |
|
$ |
(1,913 |
) |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
Other expense related to secondary offering, net of tax of $(634) and $(1,746) for quarter and nine months ended September 30, 2014, respectively |
|
$ |
799 |
|
$ |
— |
|
$ |
2,486 |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense, net of tax of $(9,122) and $(7,766) for quarter 2014 and 2013, respectively and $(24,731) and $(23,267) for nine months 2014 and 2013, respectively |
|
$ |
11,483 |
|
$ |
11,214 |
|
$ |
35,224 |
|
$ |
33,597 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-based compensation expense, net of tax of $(470) and $(435) for quarter 2014 and 2013, respectively and $(1,490) and $(1,304) for nine months 2014 and 2013, respectively |
|
$ |
592 |
|
$ |
627 |
|
$ |
2,122 |
|
$ |
1,882 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring expense, net of tax of $(162) and $(540) for quarter 2014 and 2013, respectively and $(2,024) and $(2,041) for nine months 2014 and 2013, respectively |
|
$ |
204 |
|
$ |
779 |
|
$ |
2,882 |
|
$ |
2,947 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on early debt extinguishment, net of tax of ($12,078) for quarter 2013 and $(27,389) and $(12,078) for nine months 2014 and 2013, respectively |
|
$ |
— |
|
$ |
17,441 |
|
$ |
39,008 |
|
$ |
17,441 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination of CD&R Consulting Agreement, net of tax of ($8,183) for quarter and nine months ended September 30, 2013 |
|
$ |
— |
|
$ |
11,817 |
|
$ |
— |
|
$ |
11,817 |
|
|
Net income (loss) attributable to Envision Healthcare Holdings, Inc., adjusted |
|
$ |
65,854 |
|
$ |
34,215 |
|
$ |
157,331 |
|
$ |
65,771 |
|
|
Adjusted EPS |
|
$ |
0.35 |
|
$ |
0.21 |
|
$ |
0.83 |
|
$ |
0.45 |
|
6
Envision Healthcare Holdings, Inc.
Reconciliation of Adjusted EBITDA to Net Income (Loss)
(unaudited; in thousands)
|
|
|
Quarter ended September 30, |
|
Nine months ended September 30, |
|
|
|
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
$ |
152,233 |
|
$ |
121,670 |
|
$ |
396,402 |
|
$ |
328,537 |
|
|
Depreciation and amortization expense |
|
(36,796 |
) |
(35,175 |
) |
(108,786 |
) |
(104,552 |
) |
|
Restructuring charges |
|
(366 |
) |
(1,319 |
) |
(4,906 |
) |
(4,988 |
) |
|
Interest income from restricted assets |
|
(175 |
) |
(2 |
) |
(507 |
) |
(634 |
) |
|
Equity-based compensation expense |
|
(1,062 |
) |
(1,062 |
) |
(3,612 |
) |
(3,186 |
) |
|
Related party management fees |
|
— |
|
(20,609 |
) |
— |
|
(23,109 |
) |
|
Net income (loss) attributable to noncontrolling interest |
|
67 |
|
— |
|
(3,233 |
) |
— |
|
|
Income from operations |
|
113,901 |
|
63,503 |
|
275,358 |
|
192,068 |
|
|
Interest income from restricted assets |
|
175 |
|
2 |
|
507 |
|
634 |
|
|
Interest expense, net |
|
(25,742 |
) |
(46,772 |
) |
(84,793 |
) |
(148,526 |
) |
|
Realized gains (losses) on investments |
|
(466 |
) |
158 |
|
648 |
|
276 |
|
|
Other income (expense), net |
|
(660 |
) |
(52 |
) |
(3,432 |
) |
(13,022 |
) |
|
Loss on early debt extinguishment |
|
— |
|
(29,519 |
) |
(66,397 |
) |
(29,641 |
) |
|
Income tax benefit (expense) |
|
(34,437 |
) |
4,949 |
|
(49,700 |
) |
(3,932 |
) |
|
Equity in earnings of unconsolidated subsidiary |
|
72 |
|
68 |
|
185 |
|
230 |
|
|
Net (income) loss attributable to noncontrolling interest |
|
(67 |
) |
— |
|
3,233 |
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Envision Healthcare Holdings, Inc. |
|
$ |
52,776 |
|
$ |
(7,663 |
) |
$ |
75,609 |
|
$ |
(1,913 |
) |
7
Envision Healthcare Holdings, Inc.
Reconciliation of Segment Adjusted EBITDA to Income from Operations
(unaudited; in thousands)
|
|
|
Quarter ended September 30, |
|
Nine months ended September 30, |
|
|
|
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
|
EmCare |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
$ |
99,726 |
|
$ |
82,032 |
|
$ |
258,179 |
|
$ |
218,767 |
|
|
Depreciation and amortization expense |
|
(18,030 |
) |
(16,434 |
) |
(50,949 |
) |
(49,423 |
) |
|
Restructuring charges |
|
25 |
|
(682 |
) |
(872 |
) |
(934 |
) |
|
Interest income from restricted assets |
|
(64 |
) |
109 |
|
(174 |
) |
(301 |
) |
|
Equity-based compensation expense |
|
(478 |
) |
(457 |
) |
(1,626 |
) |
(1,370 |
) |
|
Related party management fees |
|
— |
|
(8,862 |
) |
— |
|
(9,937 |
) |
|
Net income (loss) attributable to noncontrolling interest |
|
67 |
|
— |
|
(3,233 |
) |
— |
|
|
Income from operations |
|
$ |
81,246 |
|
$ |
55,706 |
|
$ |
201,325 |
|
$ |
156,802 |
|
|
|
|
|
|
|
|
|
|
|
|
|
AMR |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
$ |
52,507 |
|
$ |
39,623 |
|
$ |
138,223 |
|
$ |
109,843 |
|
|
Depreciation and amortization expense |
|
(18,766 |
) |
(18,741 |
) |
(57,837 |
) |
(55,129 |
) |
|
Restructuring charges |
|
(391 |
) |
(637 |
) |
(4,034 |
) |
(4,054 |
) |
|
Interest income from restricted assets |
|
(111 |
) |
(111 |
) |
(333 |
) |
(333 |
) |
|
Equity-based compensation expense |
|
(584 |
) |
(605 |
) |
(1,986 |
) |
(1,816 |
) |
|
Related party management fees |
|
— |
|
(11,747 |
) |
— |
|
(13,172 |
) |
|
Income from operations |
|
$ |
32,655 |
|
$ |
7,782 |
|
$ |
74,033 |
|
$ |
35,339 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Envision Healthcare Holdings, Inc. |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA and Income from operations |
|
$ |
— |
|
$ |
15 |
|
$ |
— |
|
$ |
(73 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
$ |
152,233 |
|
$ |
121,670 |
|
$ |
396,402 |
|
$ |
328,537 |
|
|
Depreciation and amortization expense |
|
(36,796 |
) |
(35,175 |
) |
(108,786 |
) |
(104,552 |
) |
|
Restructuring charges |
|
(366 |
) |
(1,319 |
) |
(4,906 |
) |
(4,988 |
) |
|
Interest income from restricted assets |
|
(175 |
) |
(2 |
) |
(507 |
) |
(634 |
) |
|
Equity-based compensation expense |
|
(1,062 |
) |
(1,062 |
) |
(3,612 |
) |
(3,186 |
) |
|
Related party management fees |
|
— |
|
(20,609 |
) |
— |
|
(23,109 |
) |
|
Net income (loss) attributable to noncontrolling interest |
|
67 |
|
— |
|
(3,233 |
) |
— |
|
|
Income from operations |
|
$ |
113,901 |
|
$ |
63,503 |
|
$ |
275,358 |
|
$ |
192,068 |
|
8
Envision Healthcare Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
|
|
|
September 30,
2014 |
|
December 31,
2013 |
|
|
|
|
(Unaudited) |
|
(Audited) |
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
247,170 |
|
$ |
204,712 |
|
|
Trade and other accounts receivable, net |
|
913,413 |
|
801,146 |
|
|
Other current assets |
|
103,832 |
|
76,425 |
|
|
Total current assets |
|
1,264,415 |
|
1,082,283 |
|
|
Non-current assets: |
|
|
|
|
|
|
Property, plant and equipment, net |
|
203,405 |
|
194,715 |
|
|
Goodwill and other intangible assets, net |
|
3,079,382 |
|
2,949,368 |
|
|
Other long-term assets |
|
47,292 |
|
73,651 |
|
|
Total assets |
|
$ |
4,594,494 |
|
$ |
4,300,017 |
|
|
|
|
|
|
|
|
|
Liabilities and Equity |
|
|
|
|
|
|
Current liabilities |
|
$ |
514,375 |
|
$ |
451,329 |
|
|
Long-term debt and capital lease obligations |
|
2,029,095 |
|
1,895,381 |
|
|
Long-term deferred tax liabilities |
|
151,225 |
|
151,130 |
|
|
Insurance reserves and other long-term liabilities |
|
184,335 |
|
192,424 |
|
|
Total liabilities |
|
2,879,030 |
|
2,690,264 |
|
|
Total equity |
|
1,715,464 |
|
1,609,753 |
|
|
Total liabilities and equity |
|
$ |
4,594,494 |
|
$ |
4,300,017 |
|
9
Envision Healthcare Holdings, Inc.
Condensed Consolidated Statements of Cash Flows and Reconciliation of Net Cash Provided by (Used in)
Operating Activities to Adjusted Free Cash Flow
(unaudited; in thousands)
|
|
|
Quarter ended September 30, |
|
Nine months ended September 30, |
|
|
|
|
2014 |
|
2013 |
|
2014 |
|
2013 |
|
|
Cash Flows from Operating Activities |
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
52,843 |
|
$ |
(7,663 |
) |
$ |
72,376 |
|
$ |
(1,913 |
) |
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
|
|
Depreciation, amortization, and other |
|
38,598 |
|
40,633 |
|
117,896 |
|
122,140 |
|
|
Excess tax benefits from equity-based compensation |
|
(22,862 |
) |
— |
|
(38,520 |
) |
(3,168 |
) |
|
Loss on early debt extinguishment |
|
— |
|
29,519 |
|
66,397 |
|
29,641 |
|
|
Deferred income taxes |
|
970 |
|
88 |
|
1,456 |
|
4,319 |
|
|
Payment of dissenting shareholder settlement |
|
— |
|
— |
|
— |
|
(13,717 |
) |
|
Changes in operating assets/liabilities, net of acquisitions: |
|
|
|
|
|
|
|
|
|
|
Trade and other accounts receivable, net |
|
(34,325 |
) |
(71,543 |
) |
(92,537 |
) |
(126,506 |
) |
|
Parts and supplies inventory |
|
(151 |
) |
(335 |
) |
(574 |
) |
(489 |
) |
|
Prepaids and other current assets |
|
7,968 |
|
3,308 |
|
(10,959 |
) |
(8,997 |
) |
|
Accounts payable and accrued liabilities |
|
53,742 |
|
32,468 |
|
85,008 |
|
22,520 |
|
|
Insurance accruals |
|
3,281 |
|
5,247 |
|
(6,539 |
) |
1,795 |
|
|
Net cash provided by (used in) operating activities |
|
100,064 |
|
31,722 |
|
194,004 |
|
25,625 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities |
|
|
|
|
|
|
|
|
|
|
Purchases of available-for-sale securities |
|
(49,282 |
) |
— |
|
(52,654 |
) |
(2,615 |
) |
|
Sales and maturities of available-for-sale securities |
|
29,898 |
|
— |
|
40,425 |
|
7,616 |
|
|
Purchases of property, plant and equipment |
|
(22,179 |
) |
(19,295 |
) |
(55,659 |
) |
(45,493 |
) |
|
Proceeds from sale of property, plant and equipment |
|
83 |
|
68 |
|
2,299 |
|
396 |
|
|
Acquisition of businesses, net of cash received |
|
37 |
|
(25,935 |
) |
(199,261 |
) |
(27,358 |
) |
|
Net change in insurance collateral |
|
808 |
|
3,282 |
|
2,021 |
|
(2,121 |
) |
|
Other investing activities |
|
589 |
|
(404 |
) |
(1,774 |
) |
(456 |
) |
|
Net cash used in investing activities |
|
(40,046 |
) |
(42,284 |
) |
(264,603 |
) |
(70,031 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities |
|
|
|
|
|
|
|
|
|
|
Issuance of common stock |
|
— |
|
1,110,900 |
|
— |
|
1,112,017 |
|
|
Borrowings under the Term Loan |
|
— |
|
— |
|
— |
|
150,000 |
|
|
Borrowings under the ABL Facility |
|
— |
|
— |
|
50,000 |
|
345,440 |
|
|
Proceeds from issuance of senior notes |
|
— |
|
— |
|
740,625 |
|
— |
|
|
Repayments of the Term Loan |
|
(3,343 |
) |
(3,339 |
) |
(6,686 |
) |
(10,028 |
) |
|
Repayments of the ABL Facility |
|
— |
|
(27,500 |
) |
(50,000 |
) |
(470,440 |
) |
|
Repayment of PIK Notes and senior notes |
|
— |
|
(450,000 |
) |
(607,750 |
) |
(450,000 |
) |
|
Payments for debt extinguishment premiums |
|
— |
|
(12,386 |
) |
(37,630 |
) |
(12,386 |
) |
|
Debt issue costs |
|
(847 |
) |
— |
|
(2,221 |
) |
(5,011 |
) |
|
Equity issuance costs |
|
— |
|
(62,020 |
) |
— |
|
(63,420 |
) |
|
Proceeds from stock options exercised |
|
7,405 |
|
— |
|
7,405 |
|
|
|
|
Excess tax benefits from equity-based compensation |
|
22,862 |
|
— |
|
38,520 |
|
3,168 |
|
|
Shares repurchased for tax withholdings |
|
— |
|
— |
|
(14,430 |
) |
— |
|
|
Proceeds from non-controlling interest |
|
— |
|
— |
|
250 |
|
— |
|
|
Payment of dissenting shareholder settlement |
|
— |
|
— |
|
— |
|
(38,336 |
) |
|
Other financing activities |
|
(1,528 |
) |
(6,364 |
) |
(5,026 |
) |
1,331 |
|
|
Net cash provided by (used in) financing activities |
|
24,549 |
|
549,291 |
|
113,057 |
|
562,335 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in cash and cash equivalents |
|
84,567 |
|
538,729 |
|
42,458 |
|
517,929 |
|
|
Cash and cash equivalents, beginning of period |
|
162,603 |
|
37,032 |
|
204,712 |
|
57,832 |
|
|
Cash and cash equivalents, end of period |
|
$ |
247,170 |
|
$ |
575,761 |
|
$ |
247,170 |
|
$ |
575,761 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating and non-acquisition investing cash flow |
|
$ |
59,981 |
|
$ |
15,373 |
|
$ |
128,662 |
|
$ |
(17,048 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Non-recurring cash flow adjustments: |
|
|
|
|
|
|
|
|
|
|
Excess tax benefits from equity-based compensation |
|
22,862 |
|
— |
|
38,520 |
|
3,168 |
|
|
Termination of CD&R Consulting Agreement |
|
— |
|
20,000 |
|
— |
|
20,000 |
|
|
FEMA and contract exit costs |
|
— |
|
— |
|
— |
|
24,500 |
|
|
Payment of dissenting shareholder settlement |
|
— |
|
— |
|
— |
|
13,717 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Free Cash Flow |
|
$ |
82,843 |
|
$ |
35,373 |
|
$ |
167,182 |
|
$ |
44,337 |
|
10
